ES2067256T3 - Peptidos biologicamente activos que contienen d-2-alquiltriptofano. - Google Patents

Peptidos biologicamente activos que contienen d-2-alquiltriptofano.

Info

Publication number
ES2067256T3
ES2067256T3 ES91920995T ES91920995T ES2067256T3 ES 2067256 T3 ES2067256 T3 ES 2067256T3 ES 91920995 T ES91920995 T ES 91920995T ES 91920995 T ES91920995 T ES 91920995T ES 2067256 T3 ES2067256 T3 ES 2067256T3
Authority
ES
Spain
Prior art keywords
peptides containing
tryptophane
alkyl
biologically active
active peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91920995T
Other languages
English (en)
Inventor
Romano Deghenghi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2067256T3 publication Critical patent/ES2067256T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PEPTIDOS QUE CONTIENEN, AL MENOS, UN RESIDUO DE D UILTRIPTOFANO EN SU CADENA AMINOACIDA Y QUE TIENEN ACTIVIDAD FARMACOLOGICA SIMILAR A LA DE LOS PEPTIDOS ANALOGOS QUE CONTIENEN RESIDUOS DE D-TRIPTOFANO NATURAL NO SUBSTITUIDO EN LUGAR DE, AL MENOS, UN D SON MAS RESISTENTES A LA DEGRADACION OXIDATIVA, QUE SUELE TENER LUGAR, POR EJEMPLO, EN PRESENCIA DE RADICALES REACTIVOS O DURANTE LA ESTERILIZACION HIPERENERGETICA, QUE LOS PEPTIDOS QUE CONTIENEN TRIPTOFANO NO SUBSTITUIDO.
ES91920995T 1990-05-11 1991-04-17 Peptidos biologicamente activos que contienen d-2-alquiltriptofano. Expired - Lifetime ES2067256T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT20273A IT1240643B (it) 1990-05-11 1990-05-11 Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano

Publications (1)

Publication Number Publication Date
ES2067256T3 true ES2067256T3 (es) 1995-03-16

Family

ID=11165335

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91920995T Expired - Lifetime ES2067256T3 (es) 1990-05-11 1991-04-17 Peptidos biologicamente activos que contienen d-2-alquiltriptofano.

Country Status (13)

Country Link
EP (1) EP0531461B1 (es)
JP (1) JP3319595B2 (es)
KR (1) KR100216386B1 (es)
AT (1) ATE114321T1 (es)
AU (1) AU657475B2 (es)
CA (1) CA2081450C (es)
DE (1) DE69105270T2 (es)
DK (1) DK0531461T3 (es)
ES (1) ES2067256T3 (es)
GR (1) GR3015146T3 (es)
HK (1) HK1006173A1 (es)
IT (1) IT1240643B (es)
WO (1) WO1991018016A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872100A (en) * 1990-05-11 1999-02-16 Deghenghi; Romano Peptides containing D-2-Alkyl-Tryptophan
EP1082959A1 (en) 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
AU6010394A (en) * 1993-02-23 1994-09-14 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonist
DE69528531T2 (de) * 1994-09-27 2003-06-05 Ardana Bioscience Ltd., Edinburgh D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
IT1277391B1 (it) * 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
IT1277113B1 (it) * 1995-12-20 1997-11-04 Romano Deghenghi Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita
WO1998019705A1 (en) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
CA2290592A1 (en) 1997-05-13 1998-11-19 Michael Anthony Cawthorne Somatostatin and somatostatin agonists for decreasing body weight
EP0981364B1 (en) 1997-05-13 2006-03-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Method and compositions for treating hyperlipidemia
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
JP4116097B2 (ja) 1997-06-20 2008-07-09 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン放出特性をもつ化合物
ATE470671T1 (de) 1998-01-16 2010-06-15 Helsinn Therapeutics Us Inc Verbindungen mit wachstumshormon-freisetzender eigenschaft
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
NZ530007A (en) 2001-06-08 2006-02-24 Sod Conseils Rech Applic Somatostatin-dopamine chimeric analogues that retain both somatostatin and dopamine activity in vivo and display enhanced biological activity
US7179784B2 (en) * 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
EP1444988A4 (en) 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
CA2523197C (en) 2003-04-22 2016-05-24 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide vectors
BRPI0515372B8 (pt) 2004-09-17 2021-05-25 Durect Corp composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
WO2009150470A2 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
EP2310028B1 (en) 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
CN121127483A (zh) * 2023-05-18 2025-12-12 港大科桥有限公司 对天然肽色氨酸残基的精确后期修饰

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1080470A (en) * 1963-12-31 1967-08-23 Merck & Co Inc Indole derivatives
WO1983002272A1 (en) * 1981-12-28 1983-07-07 Beckman Instruments Inc Synthetic peptides having pituitary growth hormone releasing activity
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides

Also Published As

Publication number Publication date
KR100216386B1 (ko) 1999-08-16
WO1991018016A1 (en) 1991-11-28
AU657475B2 (en) 1995-03-16
JPH05507066A (ja) 1993-10-14
IT9020273A0 (it) 1990-05-11
EP0531461A1 (en) 1993-03-17
CA2081450C (en) 2001-03-27
IT9020273A1 (it) 1991-11-11
AU7699791A (en) 1991-12-10
EP0531461B1 (en) 1994-11-23
DE69105270D1 (de) 1995-01-05
JP3319595B2 (ja) 2002-09-03
ATE114321T1 (de) 1994-12-15
DK0531461T3 (da) 1995-05-15
CA2081450A1 (en) 1991-11-12
IT1240643B (it) 1993-12-17
GR3015146T3 (en) 1995-05-31
DE69105270T2 (de) 1995-04-13
HK1006173A1 (en) 1999-02-12

Similar Documents

Publication Publication Date Title
ATE114321T1 (de) D-2-alkyltryptophan enthaltende biologisch aktive peptide.
DK0493480T3 (da) Dehydrodidemnin B
FR2663837B1 (fr) Prothese articulee du ligament croise anterieur du genou humain.
ATE136221T1 (de) Osteo-induktive pharmazeutische formulierungen
DE69331586D1 (de) Verbessertes femorales manschettenimplantat
ES2151921T3 (es) Analogo de dolastatina.
ES2030124T3 (es) Dispositivo para la aplicacion de implantes.
ES2070322T3 (es) Polipeptidos biologicamente activos basados en las secuencias del factor de crecimiento de transformacion beta.
NZ227787A (en) Peptides and compositions having growth hormone regulatory effects
KR900701995A (ko) 직물의 세탁 및 소독용 조성물
IT9067125A0 (it) Protesi valvolare cardiaca
ES2063354T3 (es) Dispositivo de refuerzo y de sosten del ligamento de los rotadores de una articulacion del hombro de una persona.
DE3868910D1 (de) Implantat zur befestigung von zahnprothesen.
MX9401312A (es) Nuevo procedimiento para la elaboracion del liofilizado cetrorelix.
EE9700081A (et) Keratinotsüüdi kasvufaktori analoogid
ES2113354T3 (es) Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
MX9100051A (es) Mezcla esterilizante y metodo de esterilizacion
DE3784464D1 (de) Verwendung kurzkettiger alkansulfonsaeuren in reinigungs- und desinfektionsmitteln.
BR9400578A (pt) Próteses de fixação dupla
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
FR2683715B1 (fr) Prothese textile de ligament croise anterieur du genou.
ES2180948T3 (es) Peptido que proviene de una forma soluble de la acetilcolinesterasa, activo como modulador del canal.
FI956050A7 (fi) Biologisesti aktiiviset vasopressiinianalogit
IL95863A0 (en) Anticoagulant peptides and compositions containing them
GR3021660T3 (en) Anticoagulant peptides

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 531461

Country of ref document: ES